(Q24246199)

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

The clinical trial protocol of the Metrifonate in Alzheimer's Trial (MALT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from the MALT clinical trial. Metrifonate in Alzheimer's Disease Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

The cholinergic hypothesis of geriatric memory dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

Effect of subchronic treatment with metrifonate and tacrine on brain cholinergic function in aged F344 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

A comparison of the effects of two inhibitors on brain cholinesterase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

Metrifonate. Summary of toxicological and pharmacological information available

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

Transformation and action of metrifonate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

Preferential inhibition of acetylcholinesterase molecular forms in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

Acute and subacute toxicity of several insecticides to chicks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

Cholinesterase inhibitors increase secretion of APPs in rat brain cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

7 January 2021

Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

7 January 2021

Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

7 January 2021

Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer disease. The Metrifonate Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

7 January 2021

The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003155.PUB3

7 January 2021

10.1002/14651858.CD003155.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

298542

298542

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference